Dual-Functional Phages for Angiogenin Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments lack effective methods to inhibit tumor growth by targeting angiogenin, a potent angiogenic factor that promotes tumor angiogenesis and metastasis, due to limited tumor-specific targeting capabilities.
Innovation Solution
Development of dual-functional phages equipped with tumor-homing peptides and angiogenin-binding peptides that selectively target and capture angiogenin, inhibiting its angiogenic activity and thereby suppressing tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments are used, then tumor growth can be inhibited through general mechanisms, but there is a lack of effective tumor-specific targeting capabilities against angiogenin
Solution Approach 1:
The patent combines two distinct functional peptides into a single dual-functional phage system: a tumor-homing peptide (e.g., RGD peptide) that targets tumor vasculature, and an angiogenin-binding peptide (e.g., derived from FHL3) that specifically binds angiogenin. This merging allows the single phage carrier to simultaneously achieve tumor-specific accumulation and angiogenin inhibition, resolving the contradiction between targeting reliability and functional versatility
Solution Approach 2:
The phage particle is designed as a multi-functional platform that performs multiple roles: (1) tumor targeting via surface-displayed homing peptides, (2) angiogenin capture via binding peptides, and (3) potential gene delivery function. This universal design enables one system to address multiple therapeutic needs, achieving both specific targeting and effective angiogenin inhibition
2Productivity
If angiogenin is blocked to inhibit angiogenesis, then tumor growth can be suppressed, but current methods lack effective delivery and targeting mechanisms
Solution Approach 1:
The phage system exhibits self-service characteristics by autonomously navigating to the tumor site through the tumor-homing peptide that recognizes tumor-specific markers (e.g., integrins on endothelial cells). The phage automatically accumulates in the tumor vasculature and releases its cargo, eliminating the need for complex external delivery infrastructure or sophisticated manufacturing processes while maintaining high angiogenesis inhibition efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dual-functional phages effectively inhibit tumor angiogenesis and growth by selectively accumulating in tumors and binding to angiogenin, reducing microvessel density and tumor volume while maintaining safety and compatibility with normal tissues.
Implementation Method 1
The dual-functional phages effectively inhibit tumor angiogenesis and growth by selectively accumulating in tumors and binding to angiogenin
Data Source
AI summary
Carrier compositions, including human-safe phages, equipped with one or more angiogenin-binding peptides, and optionally with tumor-homing peptides for use in anti-tumor therapies, are described. The angiogenin-binding peptides bind to and inactivate angiogenin molecules thereby blocking their angiogenic activity thus inhibiting angiogenesis in the tissue in which the compositions are localized.